New €230K contract signed with a leading global biopharmaceutical company
MEDIAN Technologies will deploy its LMS applications on 20 sites in Europe and the US, as part of a Phase I study on patients with undifferentiated malignant solid tumors.
MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer, and a service provider for image interpretation and management in oncology clinical trials, today announced that it has signed a new €230K firm contract with one of its top 10 biopharmaceutical company client.
In this project, imaging data will be acquired in 20 clinical sites, located in Europe and in the US for a total of 70 patients enrolled. The project will start immediately.
“Signing a second contract with this global biopharmaceutical company is of prime importance to us and demonstrates the growing interest of biopharmaceutical companies regarding our cutting-edge technology. During the trial, MEDIAN LMS – Lesion Management Solutions- will be deployed directly at investigator sites and will enable to decrease image interpretation variability among readers and provide the biopharmaceutical sponsor with more rapid access to imaging data as well. Sites will benefit from MEDIAN LMS technology to assess the evolution of tumor volume, an advanced imaging biomarker, enabling a better evaluation of patient response to therapy”, said Nicolas Dano, Director of Business Development Europe and Asia.
As a reminder, MEDIAN Technologies announced on Sept. 26 the signing of a new contract with another of its top 10 biopharmaceutical company client. “Our company is now sustaining its positioning toward major global biopharmaceutical companies”, added Jerome Windsor, VP Pharma Business at MEDIAN.
Since the beginning of 2013, MEDIAN Technologies has recorded €3.9M (eq. $5.3M) of orders, including €1.0M of firm orders and €2.9M of project awards [*].
[*] A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”